Eprinomectin + Esafoxolaner + Praziquantel

Verify with FDA CVM →

2,563 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
2,563
Total Reports
186
Deaths Reported
730.0%
Death Rate

Active Ingredients

EprinomectinEsafoxolanerPraziquantel

Administration Routes

TopicalUnknownOralOphthalmicIntraocularSubcutaneousTransdermalTransplacental

Species Affected

Cat 2,417
Unknown 98
Human 36
Dog 11
Bobcat 1

Most Affected Breeds

Domestic Shorthair 1,487
Cat (unknown) 331
Domestic Longhair 185
Domestic Mediumhair 142
Unknown 136
Siamese 53
Maine Coon 39
Ragdoll 25
Mixed (Cat) 22
Crossbred Feline/cat 20

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 406
Vomiting 310
Application site hair loss 232
Hypersalivation 226
Foaming at the mouth 203
Accidental exposure 189
Drooling 173
Lack of efficacy (ectoparasite) - flea 157
Not eating 153
Ataxia 147
Lack of efficacy (endoparasite) - roundworm NOS 138
Lack of efficacy (endoparasite) - tapeworm 127

Outcome Breakdown

Outcome Unknown
1,428 (57.7%)
Recovered/Normal
677 (27.4%)
Ongoing
178 (7.2%)
Euthanized
94 (3.8%)
Died
93 (3.8%)
Recovered with Sequela
3 (0.1%)

Data Summary

Metric Value
Total adverse event reports 2,563
Reports involving death 186
Case-fatality rate (reported events) 730.0%
Distinct species in reports 5
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 3

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Eprinomectin + Esafoxolaner + Praziquantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 2,563 adverse event reports referencing Eprinomectin + Esafoxolaner + Praziquantel, including 186 reports in which the animal died — a 730.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Eprinomectin, Esafoxolaner, Praziquantel. Reported administration routes include Topical, Unknown, Oral, Ophthalmic. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Eprinomectin + Esafoxolaner + Praziquantel reports are Cat (2,417 reports), Unknown (98 reports), Human (36 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (1,487), Cat (unknown) (331), Domestic Longhair (185) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Eprinomectin + Esafoxolaner + Praziquantel are Lethargy (see also Central nervous system depression in Neurological) (406), Vomiting (310), Application site hair loss (232), Hypersalivation (226). Of the 2,473 reports with a coded outcome, Outcome Unknown is the leading category at 57.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Eprinomectin + Esafoxolaner + Praziquantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial